Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DURAMORPH PF vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Morphine is a full opioid agonist that primarily acts on mu-opioid receptors in the central nervous system to produce analgesia, euphoria, and sedation. It also interacts with kappa and delta receptors. It inhibits ascending pain pathways and alters pain perception and response.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Management of moderate to severe pain when continuous opioid analgesia is needed for an extended period,Off-label: epidural or intrathecal administration for postoperative pain,Off-label: treatment of dyspnea in palliative care
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
0.8 to 10 mg via epidural injection as a single dose or via continuous epidural infusion at 0.1 to 1 mg/hour. For intrathecal use: 0.2 to 1 mg as a single dose. Intravenous: 2 to 10 mg for analgesia every 2-4 hours as needed.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life of morphine is approximately 2-4 hours in adults. In neonates and elderly, half-life may be prolonged (up to 4.5-6.5 hours). Context: half-life may be extended in renal impairment due to accumulation of active metabolites.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Primarily hepatic via glucuronidation by UGT2B7 to morphine-3-glucuronide (M3G, inactive) and morphine-6-glucuronide (M6G, active); minor metabolism via CYP2D6 to normorphine.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Primarily renal (approximately 90% as morphine-3-glucuronide and morphine-6-glucuronide, with 10% as unchanged morphine). Biliary/fecal excretion accounts for less than 10%.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
30-35% bound to albumin.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
3-5 L/kg (range 1-6 L/kg). Clinical meaning: indicates extensive tissue distribution.
4-6 L/kg; large Vd indicates extensive tissue distribution
Epidural/Intrathecal: effectively 100% at site of action (systemic bioavailability from epidural absorption is ~30-40% due to first-pass metabolism). Oral: 20-40% (not relevant for DURAMORPH PF).
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
GFR 50-90 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 25-50% and extend dosing interval; GFR <10 m L/min: avoid use or reduce dose by 50% and administer every 6-8 hours with close monitoring.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 25-50% and monitor; Child-Pugh Class C: avoid use or reduce dose by 50% and extend dosing interval.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Epidural: 0.03 to 0.05 mg/kg as a single dose, may repeat every 4-6 hours; continuous infusion: 0.002 to 0.008 mg/kg/hour. Intrathecal: 0.01 to 0.02 mg/kg as a single dose. Intravenous: 0.05 to 0.1 mg/kg every 2-4 hours prn.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Reduce initial dose by 25-50% and titrate cautiously due to increased sensitivity and risk of respiratory depression. Use non-PVC tubing and avoid in renal impairment.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; NEONATAL OPIOID WITHDRAWAL SYNDROID; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS. Ensure proper patient selection, monitoring, and dispensing.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Risk of respiratory depression, especially in elderly, cachectic, or debilitated patients; central nervous system depression; serotonin syndrome with serotonergic drugs; adrenal insufficiency; hypotension; seizures; severe hypotension; use in patients with head injury; use in patients with biliary tract disease; use in patients with pancreatic disease; use in patients with renal impairment; use in patients with hepatic impairment; use in patients with respiratory conditions; use in patients with gastrointestinal obstruction; use in patients with prostatic hyperplasia; use in patients with urinary retention; use in patients with hypothyroidism; use in patients with adrenocortical insufficiency; use in patients with toxic psychosis; use in patients with alcoholism; use in patients with delirium tremens; use in patients with kyphoscoliosis; use in patients with severe obesity; use in patients with sleep apnea; use in patients with myxedema; use in patients with chronic obstructive pulmonary disease; use in patients with cor pulmonale; use in patients with respiratory depression; use in patients with acute or severe bronchial asthma; use in patients with paralytic ileus; use in patients with hypersensitivity to morphine; use in patients with gastrointestinal obstruction; weaning from opioids; physical dependence; withdrawal; tolerance; impaired mental or physical abilities; driving; operating machinery; risk of overdose; accidental ingestion; neonatal opioid withdrawal syndrome; concomitant use with alcohol; concomitant use with benzodiazepines; concomitant use with CNS depressants; abuse potential; monitoring; pregnancy; lactation; renal impairment; hepatic impairment; elderly; pediatric; recent intracranial surgery; increased intracranial pressure; impaired consciousness; coma; convulsive disorders; hypotension; hypovolemia; severe pulmonary disease; respiratory depression; sleep-related breathing disorders; drug dependence; misuse; addiction; abuse; diversion; storage and disposal.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hypersensitivity to morphine or any component of the formulation; significant respiratory depression; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction, including paralytic ileus; concomitant use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy; respiratory depression in the absence of resuscitative equipment; upper airway obstruction; status asthmaticus; severe chronic obstructive pulmonary disease; cor pulmonale; severe obesity; sleep apnea syndrome; myxedema; delirium tremens; acute alcoholism; increased intracranial pressure; head injury; intracranial lesions; impaired consciousness; coma; convulsive disorders; hypotension; hypovolemia; biliary tract surgery; suspected surgical abdomen; pancreatitis; prostatic hyperplasia; urethral stricture; urinary retention; use in pregnancy when premature delivery is anticipated; during labor when delivery of a premature infant is anticipated; during labor when narcotic antagonist is not available; use in breastfeeding; use in children less than 18 years (except as directed by a physician).
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Avoid alcohol and grapefruit juice for at least 24 hours after administration. Alcohol potentiates CNS depression and respiratory effects. No specific food restrictions beyond standard postoperative diet; however, patients should avoid large meals if nauseated. Maintain adequate fluid and fiber intake to mitigate constipation.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
Preservative-free morphine (Duramorph PF) is FDA Pregnancy Category C. First trimester: Limited human data; animal studies show increased risk of neural tube defects and skeletal anomalies at high doses. Second and third trimesters: Chronic use may cause fetal opioid dependence and neonatal opioid withdrawal syndrome (NOWS) after delivery. Not associated with major congenital malformations in human studies, but risk-benefit must be assessed.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Morphine is excreted into breast milk. M/P ratio is approximately 2.5. Relative infant dose is about 9-10% of maternal weight-adjusted dose. Use with caution; monitor for infant drowsiness, respiratory depression, and constipation. American Academy of Pediatrics considers morphine compatible with breastfeeding, but avoid during labor and delivery due to potential neonatal respiratory depression.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No established dose adjustment guidelines for pregnancy. Pharmacokinetic changes: Increased volume of distribution and clearance in pregnancy may lower peak concentrations, but clinical significance is unclear. Use the lowest effective dose for the shortest duration. For epidural/intrathecal use, doses are typically adjusted by clinician based on maternal response and fetal status. Avoid high doses in third trimester due to risk of neonatal respiratory depression.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
DURAMORPH PF is a preservative-free morphine sulfate solution indicated for epidural or intrathecal administration. Onset of analgesia occurs within 10-15 minutes after epidural injection and peaks at 30-60 minutes; intrathecal onset is faster (5-10 minutes) with duration up to 24 hours. Due to risk of delayed respiratory depression, patients must be monitored in a setting equipped for resuscitation for at least 24 hours after administration. Naloxone should be readily available. Do not use if solution is discolored or contains precipitate. Avoid concurrent use with MAOIs or within 14 days of discontinuation.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
This medication is given directly into the spine to control severe pain. You will be closely monitored in the hospital. Report any trouble breathing, severe drowsiness, or itching.,Do not drive or operate machinery for at least 24 hours after administration. Avoid alcohol and sedatives, which may increase respiratory depression.,You may experience nausea, vomiting, constipation, or urinary retention. Notify your healthcare provider if these become severe.,If you have a history of opioid addiction, head injury, asthma, or kidney/liver disease, inform your doctor before treatment.,Do not breastfeed for 24 hours after receiving this medication. Inform all healthcare providers that you have received an intrathecal opioid.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DURAMORPH PF vs ABSTRAL, answered by our medical review team.
DURAMORPH PF is a Opioid Analgesic that works by Morphine is a full opioid agonist that primarily acts on mu-opioid receptors in the central nervous system to produce analgesia, euphoria, and sedation. It also interacts with kappa and delta receptors. It inhibits ascending pain pathways and alters pain perception and response.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DURAMORPH PF and ABSTRAL depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DURAMORPH PF is: 0.8 to 10 mg via epidural injection as a single dose or via continuous epidural infusion at 0.1 to 1 mg/hour. For intrathecal use: 0.2 to 1 mg as a single dose. Intravenous: 2 to 10 mg for analgesia every 2-4 hours as needed.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DURAMORPH PF and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DURAMORPH PF is classified as Category C. Preservative-free morphine (Duramorph PF) is FDA Pregnancy Category C. First trimester: Limited human data; animal studies show increased risk of neural tube defects and skeletal a. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.